Skip to main content
. 2015 Dec 14;8(3):436–453. doi: 10.1080/19420862.2015.1119352

Figure 7.

Figure 7.

CSL311 inhibits survival of cells isolated from human inflammatory airway disease tissue. Sputum cells from samples induced at baseline and 24 h after inhaled allergen challenge from allergic asthmatic subjects were incubated with (A) CSL311 (100 µg/ml) or an isotype control mAb (100 µg/ml) at 37°C for 24 h or (B) incubated with CSL311 (100 µg/ml) or an isotype control mAb (100 µg/ml) at 37°C for 24 h in the presence of 1 ng/ml each IL-3, GM-CSF and IL-5. Cells were analyzed for viability by flow cytometry. Data are expressed as percent cell viability and compared to the isotype control for each donor. Samples where the pre-incubation viability was<10% were excluded from the analysis. Non-adherent mononuclear cells (NAMC) from (C-D) bone marrow and (E-F) blood samples collected at baseline and 24 h after inhaled allergen challenge from allergic asthmatic subjects were incubated with CSL311 (100 µg/ml, filled bars) or an isotype control mAb (100 µg/ml, open bars) at 37°C for 24 h in the presence of diluent (neg) or 1 ng/ml each IL-3, GM-CSF and IL-5, or cytokines combined (All) and (C,E) GM CFU and (D,F) Eo/Baso CFU were enumerated. Data expressed as median ± range and 95% confidence intervals. A Wilcoxon matched pairs signed rank 2 tailed t-test was used to determine statistical significance: ns, not significant p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.005.